Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Nanoviricides Inc (NNVC)

Nanoviricides Inc (NNVC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 22,136
  • Shares Outstanding, K 17,997
  • Annual Sales, $ 0 K
  • Annual Income, $ -9,470 K
  • EBIT $ -8 M
  • EBITDA $ -7 M
  • 60-Month Beta 1.16
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.96

Options Overview Details

View History
  • Implied Volatility 206.50% (-15.74%)
  • Historical Volatility 123.23%
  • IV Percentile 25%
  • IV Rank 10.07%
  • IV High 776.24% on 02/11/25
  • IV Low 142.67% on 10/17/25
  • Expected Move (DTE 13) 1.2155 (98.82%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 27
  • Volume Avg (30-Day) 100
  • Put/Call OI Ratio 0.08
  • Today's Open Interest 4,088
  • Open Int (30-Day) 3,999
  • Expected Range 0.0145 to 2.4455

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.14
  • Number of Estimates 1
  • High Estimate -0.14
  • Low Estimate -0.14
  • Prior Year -0.14
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.0700 +14.95%
on 12/03/25
2.1100 -41.71%
on 11/06/25
-0.7400 (-37.56%)
since 11/05/25
3-Month
1.0700 +14.95%
on 12/03/25
2.2299 -44.84%
on 11/05/25
-0.2600 (-17.45%)
since 09/05/25
52-Week
0.9400 +30.85%
on 04/09/25
2.2299 -44.84%
on 11/05/25
-0.2300 (-15.75%)
since 12/05/24

Most Recent Stories

More News
NanoViricides Has Signed a Master Services Agreement with OnlyOrphansCote Regarding Orphan Drug Strategy of NV-387 for Treatment of MPox, Smallpox, and Measles

SHELTON, CONNECTICUT / ACCESS Newswire / December 1, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development...

NNVC : 1.2300 (+0.82%)
NanoViricides, Inc. Has Filed its Quarterly Report - Subsequent Raise Has Fortified Fiscal Position

SHELTON, CONNECTICUT / ACCESS Newswire / November 17, 2025 / NanoViricides, Inc. (NYSE Amer.:NNVC) (the "Company"), reports that it has filed its Quarterly Report on Form 10-Q for the fiscal quarter ending...

NNVC : 1.2300 (+0.82%)
NanoViricides to Present at the Pharma Partnering Summit 2025 in Boston Today, November 14th - NV-387 is Effective Against H3N2

SHELTON, CONNECTICUT / ACCESS Newswire / November 14, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs that...

NNVC : 1.2300 (+0.82%)
NanoViricides Announces Closing of $6 Million Registered Direct Offering and Concurrent Private Placement Priced at the Market Close

SHELTON, CONNECTICUT / ACCESS Newswire / November 12, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), today announced the closing of its previously announced securities purchase agreement...

NNVC : 1.2300 (+0.82%)
NanoViricides Announces Pricing of $6 Million Registered Direct Offering and Concurrent Private Placement Priced at the Market Close

SHELTON, CONNECTICUT / ACCESS Newswire / November 11, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), today announced that it has entered into a securities purchase agreement with a single...

NNVC : 1.2300 (+0.82%)
NanoViricides Has Received Approval to Start Phase II Clinical Trial of NV-387 for the Treatment of MPox by the Regulatory Agency ACOREP of the Democratic Republic of Congo

SHELTON, CONNECTICUT / ACCESS Newswire / November 10, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") today reported that it has received approval to Start Phase II Clinical Trial of NV-387...

NNVC : 1.2300 (+0.82%)
NanoViricides Annual Shareholders Meeting to be Held at 10 am on Saturday, November 5th at on Saturday, November 8, 2025, at the Hampton Inn & Suites Stamford, CT

NV-387 Could be the Answer to the MPox Clade I Rising in the USA, Says Dr. Diwan

NNVC : 1.2300 (+0.82%)
NanoViricides to Present at the Spartan Capital Investor Conference 2025 in New York City Today, November 3rd

SHELTON, CONNECTICUT / ACCESS Newswire / November 3, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs that...

NNVC : 1.2300 (+0.82%)
Treating Measles Infection: Nanoviricides CEO Dr Anil Diwan Interviewed by Steve Darling from Proactive

SHELTON, CONNECTICUT / ACCESS Newswire / October 29, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the "Company"), announced that Nanoviricides CEO Dr Anil Diwan joined Steve...

NNVC : 1.2300 (+0.82%)
NanoViricides to Present at the PODD 2025 Conference in Boston on October 27

SHELTON, CT / ACCESS Newswire / October 27, 2025 / NanoViricides, Inc. (NYSE American: NNVC ) (the "Company"), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs that the virus...

NNVC : 1.2300 (+0.82%)

Business Summary

NanoViricides, Inc. is a development stage company focused on creating special purpose nanomaterials for antiviral therapy. The Company's novel nanoviricide class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. It also focuses on the development...

See More

Key Turning Points

3rd Resistance Point 1.3133
2nd Resistance Point 1.2967
1st Resistance Point 1.2633
Last Price 1.2300
1st Support Level 1.2133
2nd Support Level 1.1967
3rd Support Level 1.1633

See More

52-Week High 2.2299
Fibonacci 61.8% 1.7372
Fibonacci 50% 1.5849
Fibonacci 38.2% 1.4327
Last Price 1.2300
52-Week Low 0.9400

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar